A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Inclusion Criteria:
Exclusion Criteria:
Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
Treatment with any of the following medications or therapies within 1 week, prior to Day 1:
St. Petersburg, Florida 33709, United States
CABA, Buenos Aires C1027AAP, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
Derqui, Pilar, Buenos Aires B1629ODT, Argentina
Buenos Aires, Distrito Federal 1425, Argentina
CABA, Distrito Federal C1012AAY, Argentina
North York, Ontario M3B 0A7, Canada
North York, Ontario M3B 3S6, Canada
Wuhan, Hubei 430022, China
Hangzhou, Zhejiang 310003, China
Hangzhou, Zhejiang 310020, China
Düsseldorf, 40225, Germany
Nagakute-shi, Aichi-ken 480-1195, Japan
Asahikawa-shi, Hokkaido 070-8610, Japan
Inashiki-gun, Ibaraki 300-0395, Japan
Nonoichi-shi, Ishikawa-ken 921-8801, Japan
Marugame-shi, Kagawa-ken 763-0074, Japan
Kawasaki-shi, Kanagawa 211-8533, Japan
Izumiotsu-shi, Osaka 595-0025, Japan
Shimotsuga-gun, Tochigi 321-0293, Japan
Itabashi-ku, Tokyo 173-8606, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Gdansk, 80-280, Poland
Wroclaw, 50-450, Poland
Matosinhos Municipality, 4464-513, Portugal
Las Palmas de Gran Canaria, Canary Islands 35010, Spain